The Royal College of Surgeons (RCS) and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) have expressed concerns that health and beauty retailer Superdrug is now offering in-store injectable treatments.
On August 15, Superdrug revealed that they had partnered with global pharmaceutical company Allergan to offer in-store injectable treatments.
In response to this, the RCS and BAPRAS have co-authored a formal letter to Mr Peter Mcnab, the CEO of AS Watson (the owner of Superdrug), explaining that they believe that offering injectables on the high-street will encourage ‘impulse buys’ of botulinum toxin. They also stated that undergoing any treatment is ‘a decision that should not be taken lightly.’
The letter asked for the company to clarify issues such as who will pay for corrective treatment, what customers should do if the procedure goes wrong or if they are unhappy, where the employees will perform the procedures and how they will ensure that toxin and fillers will not be offered on price promotions.
They also went on to suggest that all professionals performing the treatment should be registered with the Joint Council for Cosmetic Practitioners (JCCP), a requirement that Superdrug has already confirmed.
To read the letter in full, click here.